Join

Compare · OCDX vs VRAX

OCDX vs VRAX

Side-by-side comparison of Ortho Clinical Diagnostics Holdings plc (OCDX) and Virax Biolabs Group Limited (VRAX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both OCDX and VRAX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • OCDX carries a market cap of $4.08B.
  • VRAX has hit the wire 3 times in the past 4 weeks while OCDX has been quiet.
  • OCDX has more recent analyst coverage (8 ratings vs 1 for VRAX).
MetricOCDXVRAX
Company
Ortho Clinical Diagnostics Holdings plc
Virax Biolabs Group Limited
Price
$17.64+0.46%
$0.16+0.50%
Market cap
$4.08B
-
1M return
-
-13.45%
1Y return
-
-83.38%
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
2021
2022
News (4w)
0
3
Recent ratings
8
1
OCDX

Ortho Clinical Diagnostics Holdings plc

Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.

VRAX

Virax Biolabs Group Limited

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.

Latest OCDX

Latest VRAX